Last Updated: October 3, 2025
Analyzing Management
Leadership at public companies plays a crucial role for hedge funds and asset managers, both during initial due diligence and in continuous risk assessment. ManagementTrack offers a consistent framework that eliminates distractions by highlighting definitive strengths and weaknesses, identifying warning signs and positive indicators, and establishing a straightforward connection between CEO actions and financial performance.
CEO Kelderman’s CGT wins may not overcome macro & strategy issues to stabilize finances
Analysis of Bio-Techne CEO Kim Kelderman
Despite proven execution in high-growth segments like CGT, Kelderman’s struggles with macro pressures and inconsistent strategic execution may limit his ability to stabilize the company’s overall financial performance.
Management evaluated Kim Kelderman’s track record and skillset against the following key factors for TECH:
- Transitioning instruments to recurring QA/QC revenue streams.
- Executing Exosome divestiture to expand margins and fund growth.
- Sustaining CGT momentum via new product and ecosystem adoption.
- Navigating macro headwinds to stabilize growth and margins.
Kim Kelderman’s Track Record & Key Open Questions to Research
ManagementTrack provides track record analysis, career playbooks, strengths, and weaknesses for every CEO. It allows investors to dig deeper to uncover hard to find data to answer the most pressing questions.
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ for more information.
Question #1
To reignite growth, will Kelderman balance his ambition for transformative M&A with the capital allocation discipline to avoid another Exosome-like failure, or will his desire for growth lead him to again misjudge the operational complexity of deals outside his core expertise?
Question #2
Now that Kelderman is CEO and responsible for enterprise-wide profitability, will he pivot from his segment-level playbook of driving growth at the expense of margins, or will he struggle to instill the cost discipline required to navigate the current downturn and deliver on the margin expansion promised from his portfolio changes?
p>Question #3
Was Kelderman’s decisive divestiture of Exosome a sign of proactive strategic leadership that can navigate the current enterprise-wide crisis, or was it a reactive move to clean up a past failure that masks a struggle to manage the more complex, ongoing headwinds of slowing growth and margin pressure?
Why Do Investors Use ManagementTrack?
What is ManagementTrack’s assessment of Kim Kelderman at TECH?
ManagementTrack assesses an executive’s capabilities through its proprietary career analysis and in-depth interviews with former colleagues. This process identifies an individual’s historical performance, core competencies, and potential blind spots. These findings are then benchmarked against the critical success factors for TECH, which for Kelderman include: transitioning instruments to recurring revenue models, executing divestitures to expand margins, sustaining momentum in the CGT business, and navigating macroeconomic headwinds to stabilize growth.
Beyond career analysis, how does ManagementTrack predict the impact of management on future results?
ManagementTrack’s platform includes proprietary models that detect and quantify executive evasion during earnings calls, flagging any communication that deviates from the norm. Additionally, the system scrutinizes all insider trading activity to identify outlier transactions that have historically been predictive of stock over or underperformance. These data points, combined with the comprehensive ManagementTrack Rating—a forward-looking 1-10 score for each executive—provide investors with a distinct, actionable perspective on how an executive team is likely to influence future company results.
Which companies and executives does ManagementTrack cover?
ManagementTrack provides real-time, comprehensive coverage of the entire C-suite for every publicly traded company.
How to Learn More
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ to see our deep dive analysis on any executive.
Author
Colby Howard is the co-founder and President of Paragon Intel. Paragon Intel’s ManagementTrack is the premier executive analysis platform for hedge funds, asset managers, corporations, boards, and recruiters. Our proprietary data, built over a decade of analysis, allows us to analyze each public company executive to understand their fit and ability to execute at their company. We leverage our proprietary data – key quantitative research on an executive’s career plus interviews with their former colleagues – with public documents, including SEC filings (10-K, 10-Q), investor presentations, press releases, and earnings call transcripts. to build a holistic, evidence-based view of an executive’s capabilities and playbook.
Sources
- Verified Career History by ManagementTrack for Kim Kelderman
- Analysis of Capital Allocation, Performance, and Fundamentals across career by ManagementTrack
- Bio-Techne Corp. 10Q
- Bio-Techne Corp. 10K
- Bio-Techne Corp. Earnings Calls
- Bio-Techne Corp. Press Releases
Relevant Links
- For more information on ManagementTrack’s Data visit: https://paragonintel.com/management-track-data/
- For more information on ManagementTrack’s Interview & Analysis visit: https://paragonintel.com/management-track-reports/
- For more information on ManagementTrack’s Interview library visit: https://paragonintel.com/management-track-report-library/
- For more information on ManagementTrack’s Evasion Analysis visit: https://paragonintel.com/earnings-call-evasion/
- For more information on how ManagementTrack helps hedge funds and asset managers visit: https://paragonintel.com/
